Trump wants more health savings accounts. A catch: they can’t pay insurance premiums

Republican proposals and a White House-led rule change would expand HSA eligibility to more ACA enrollees (starting Jan. 1 for bronze/catastrophic plans) and include proposals to load accounts with federal dollars, as Senators such as Bill Cassidy push deposits as an alternative to expiring pandemic-era ACA premium subsidies. Key constraints remain: HSAs cannot be used to pay insurance premiums under current law, enhanced subsidies expire at year-end, and Obamacare enrollees are projected to face ~114% higher out-of-pocket premium costs next year absent action; HSA contribution limits for 2026 are $4,400 (single) and $8,750 (family). The shift would likely benefit retailers and startups selling HSA-eligible wellness products (Truemed sells items ranging from $1,700 bassinets to $9,000 ice baths) and could redirect significant consumer health spending—HSA assets rose from $5B two decades ago to $146B last year—while leaving the core premium-affordability problem largely unresolved.

Analysis

Market structure: Expanding HSA eligibility creates a concentrated winner pool — large omni-channel retailers (AMZN, WMT, TGT) and HSA-platform vendors — because incremental HSA-dollar velocity (~$146B assets today; 7.3M newly eligible) flows into eligible goods and memberships, not premiums. Insurers tied to ACA exchanges face revenue/ enrollment downside because HSAs cannot legally pay premiums and bronze-plan migration raises adverse-selection risk; expect pricing pressure on marketplace insurers and potential enrollment declines in 2026 absent a subsidy extension.

Competitive dynamics & supply/demand: Retailers with HSA storefronts gain product-margin tailwinds on higher-ticket items (kettlebells to saunas) and recurring spend (supplements, memberships), allowing modest mix-shift leverage but limited upside vs. total sales (single-digit % of revenue initially). Small specialized vendors (e.g., Truemed niche goods) may extract outsized margin but face scale, regulatory and reimbursement frictions (prescription requirements), capping long-term pricing power.

Risks & timing: Key tail risks — congressional reversal/extension of enhanced subsidies by Dec 31, litigation or stricter IRS/HHS rules, fraud/ audit headlines (expensive “wellness” items) — could reprice winners within days-weeks. Short-term (0–3 months) volatility tied to legislative signals; medium (3–12 months) reflects enrollment behavior and merchant integration; long-term (1–3 years) depends on HSA asset growth bounded by contribution caps ($4,400 single/$8,750 family in 2026).

Trading implications: Tactical overweight consumer retail & HSA-platform exposure while hedging policy and insurer downside. Favor 3–12 month call-spread exposure to AMZN/WMT for asymmetric upside; use put spreads or short exposure to ACA-sensitive insurers (e.g., CNC) as a relative hedge. Key catalysts: Senate action by Dec 31, HHS rulemaking by Jan 15, 2026, and Truemed divestiture disclosures within 30 days.

Key Decisions for Investors

• Establish a 2–3% portfolio long in AMZN via a 6–9 month call spread (buy 1 ATM call, sell 15% OTM call) to capture incremental HSA storefront revenue; trim half if a Senate vote to extend enhanced subsidies passes by Dec 31 or if AMZN falls >10% from entry.
• Add a 1–2% tactical overweight in WMT (buy 3–6 month 5% OTM call spread or simple equity) to play scale HSA purchases and brick‑and‑mortar pickup; target 6–12 month horizon, stop-loss -8% absolute or close on favorable HHS guidance limiting expanded HSA uses.
• Implement a relative-value pair: long AMZN (2%) / short Centene (CNC) (1–1.5%) or buy CNC 3‑month put spread (buy ATM, sell 15% OTM) sized to net ~1% portfolio risk to express insurer marketplace downside if subsidies lapse; unwind if CNC outperforms by >10%.
• Purchase a 3‑month S&P put (notional ~1–2% portfolio) expiring just after Dec 31 to hedge cliff risk around congressional action; monitor three catalysts—Senate vote by Dec 31, HHS HSA eligibility guidance by Jan 15, and Truemed divestiture disclosures within 30 days—and reprice positions if any trigger occurs.